LF
LARA FLYNN
LIFE SCIENCES PENNSYLVANIA · King of Prussia, PA · registered since 2024
Registered · LDAActive
At a glance
Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
4
2 agencies contacted
Activity
filings by quarter
Works on
Specific issues
Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy.
Keep legislators apprised of developments/news in the Commonwealth's life sciences ecosystem.
Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Support funding increases for the National Institutes of Health, National Science Foundation, and Food and Drug Administration Life Sciences Pennsylvania supports Federal incentivize investment in the R&D of therapies and cures for rare disorders as well as policies to improve public health and pandemic preparedness including anti-microbial resistance, PAHPA reauthorization, and substance use disorder crisis. H.R. 7384, the Creating Hope Reauthorization Act of 2024 would reauthorize the Rare Pediatric Disease Priority Review Voucher Program (PPRV). The program incentivizes the development of novel therapies to treat pediatric rare diseases. By September of 2024, the Pediatric Priority Review Voucher will expire, and Life Sciences Pennsylvania supports the reauthorization of this crucial legislation.
Support policies that strengthen IP/Patent protections - e.g. Stronger Patents Act and express concern for policies, like the TRIPS Waiver, that waive patent protections for COVID diagnostics and therapeutics, and share concerns on proposals, such as march-in rights, that undermine IP protections and innovation. Share concerns with Pennsylvania delegation specifically on Department of Commerce and HHS proposed framework for agencies on the exercise of march-in rights.
Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.